Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
BEAM · Why this verdict
Why Beam Therapeutics (BEAM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.1/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The investment case rests on a single pipeline asset, creating binary risk for holders. A clinical setback, regulatory delay, or safety signal for that program would have no offset from a diversified portfolio of candidates. Bear case | A second independent clinical-stage program advances into Phase 2 within 12 months, meaningfully reducing dependence on any single asset. | →Stable |
| CounterFocused resource allocation on one well-advanced program can be more capital-efficient than spreading a limited development budget across multiple early-stage candidates. | ||
Consensus analyst targets imply roughly 48% appreciation from current levels, suggesting the market has not priced in the full potential value of the clinical pipeline if key milestones are reached. Price targets | The stock appreciates toward the $46 consensus target over 12 months as clinical data readouts reduce binary uncertainty. | →Stable |
| CounterBiotechs trading far below analyst targets typically reflect the market pricing in a meaningful probability of clinical failure that analyst base-case models discount; the 32% short interest indicates institutional investors are actively positioned against the consensus. | ||
Short interest at 32% of the float represents an unusually high level of bearish institutional positioning, and implied volatility of 147% indicates the options market is pricing in substantial uncertainty about upcoming clinical catalysts. Risk | Short interest declines below 15% as positive clinical data resolves the key binary and forces bears to cover. | →Stable |
| CounterElevated short interest can reverse into a meaningful rally if a catalyst surprises positively, turning the bearish overhang into forced buying that amplifies any upside move. | ||
The company burns cash at a rate equivalent to 142% of revenue, placing its quality profile well below the floor needed for a durable investment. Until cash consumption narrows materially, the business must rely on external capital to sustain operations. Quality | FCF burn rate narrows toward revenue levels over the next four quarters as operating expenses stabilize relative to program milestones. | →Stable |
| CounterPre-revenue biotechs are expected to run negative free cash flow; the beat record in 3 of the last 4 quarters suggests management is executing within its budget, and the burn may be strategically appropriate for a pivotal clinical program. | ||
The investment case rests on a single pipeline asset, creating binary risk for holders. A clinical setback, regulatory delay, or safety signal for that program would have no offset from a diversified portfolio of candidates.
→StableBear case
- Expectation
- A second independent clinical-stage program advances into Phase 2 within 12 months, meaningfully reducing dependence on any single asset.
CounterFocused resource allocation on one well-advanced program can be more capital-efficient than spreading a limited development budget across multiple early-stage candidates.
Consensus analyst targets imply roughly 48% appreciation from current levels, suggesting the market has not priced in the full potential value of the clinical pipeline if key milestones are reached.
→StablePrice targets
- Expectation
- The stock appreciates toward the $46 consensus target over 12 months as clinical data readouts reduce binary uncertainty.
CounterBiotechs trading far below analyst targets typically reflect the market pricing in a meaningful probability of clinical failure that analyst base-case models discount; the 32% short interest indicates institutional investors are actively positioned against the consensus.
Short interest at 32% of the float represents an unusually high level of bearish institutional positioning, and implied volatility of 147% indicates the options market is pricing in substantial uncertainty about upcoming clinical catalysts.
→StableRisk
- Expectation
- Short interest declines below 15% as positive clinical data resolves the key binary and forces bears to cover.
CounterElevated short interest can reverse into a meaningful rally if a catalyst surprises positively, turning the bearish overhang into forced buying that amplifies any upside move.
The company burns cash at a rate equivalent to 142% of revenue, placing its quality profile well below the floor needed for a durable investment. Until cash consumption narrows materially, the business must rely on external capital to sustain operations.
→StableQuality
- Expectation
- FCF burn rate narrows toward revenue levels over the next four quarters as operating expenses stabilize relative to program milestones.
CounterPre-revenue biotechs are expected to run negative free cash flow; the beat record in 3 of the last 4 quarters suggests management is executing within its budget, and the burn may be strategically appropriate for a pivotal clinical program.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Beam Therapeutics carries roughly 48% upside to the analyst consensus target, but the investment case is undermined by cash burn equal to 142% of revenue, a pipeline concentrated in a single asset, and a 32% short interest reflecting strong institutional skepticism about the clinical risk/reward.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
2.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -142% of revenue
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 9.3 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 2.9 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.2/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 6.5 |
| Analyst rating | 8.6 |
| Price target | 9.4 |
- ▸Analyst upside: 47%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
Peer rank
4.4/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.7 |
| quality rank | 4.8 |
| growth rank | 9.9 |
- ▸Industry growth leader
Technical
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.3 |
| support resistance | 2.5 |
| 52w position | 8.9 |
| gap | 5.0 |
Risk (lower is worse)
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 0.0 |
| days to cover | 0.0 |
| volatility | 0.0 |
| put call | 7.6 |
| implied vol | 0.0 |
| beta | 2.7 |
| debt equity | 9.1 |
- ▸High short interest justified: 43%
- ▸High IV: 95%
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
| news activity | 8.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (8)
- MOMENTUM:7.2>=5.5
- ASYMMETRY:2.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:32d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
2.14
Upside
+32.1%
Downside
15.0%
Sizing output
AVOID
SetupBreakout — Golden cross, above all MAs, RSI 69, MACD bullish
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Sentiment at 8.2 could not lift the engine output above the verdict floor.
The strongest dimensions are Sentiment at 8.2, Momentum at 7.2, and Catalyst at 6.9; the weakest are Quality at 2.2, Risk (lower is worse) at 2.8, and Peer rank at 4.4. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 2.14 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Cash Burn Below Quality Floor
Trip ifFCF burn falls below -60% of revenue (improving from the current -142%) for 2 consecutive quarters.
- P2Pipeline Single Asset Concentration
Trip ifAt least 2 independent pipeline assets reach Phase 2 clinical trials or later within 12 months, bringing active clinical-stage programs to 2 or more.
- P3Analyst Consensus Material Upside
Trip ifConsensus analyst price target falls below $38 (from the current $45.96) for 3 or more covering analysts within 12 months.
- P4High Short Interest Bearish Conviction
Trip ifShort interest falls below 15% of float (from the current 32%) for 2 consecutive months.